New Perspectives Offered by Nuclear Medicine for the Imaging and Therapy of Multiple Myeloma
نویسندگان
چکیده
The management of multiple myeloma has fundamentally changed over the years and imaging techniques able to match the therapeutic advances are now much needed. Although many patients now achieve complete response after first-line treatment, relapse is common. Therefore, it would be important to improve the initial prognostic stratification and to detect minimal residual disease after treatment. (18)F-FDG-PET/CT is a useful imaging tool which has a high prognostic value at baseline evaluation and can effectively differentiate active from inactive lesions during induction treatment or after autologous stem-cell transplantation. In combination with biological data, it improves the prediction of relapse. Other PET tracers may soon enter clinical practice and overcome some of the limitations of (18)F-FDG, such as the low sensitivity in detecting early bone marrow infiltration. Excellent results with (11)C-Methionine are reported by Lapa and colleagues in this issue of the Journal. (11)C-Methionine uptake reflects the increased protein synthesis of malignant plasmocytes and correlates well with bone marrow infiltration. Other promising PET ligands include lipid tracers, such as (11)C-Choline or (11)C-acetate, and some peptide tracers, such as (68)Ga-Pentixafor, that targets CXCR4 (chemokine receptor-4), which is often expressed with high density by myeloma cells. Malignant plasma cells are radiosensitive and thus potentially amenable to systemic radionuclide therapy. Indeed, excellent preclinical results were obtained with radioimmunotherapy targeting CD38. Also, preliminary clinical results with peptides targeting CXCR4 (e.g. (177)Lu- or (90)Y-Pentixather) are encouraging. Multiple myeloma may represent a renewal of the already strong partnership between hematologists and nuclear medicine physicians.
منابع مشابه
Multiple myeloma in a patient with suspected hyperparathyroidism
Multiple myeloma (MM) is a clonal B-lymphocyte neoplasm of terminally differentiated plasma cells. Imaging modalities which allow the recognition of the effects of myeloma cells on the skeletal system have been utilized for a long time. Herein, we represent a patient with generalized osteoporosis and hypercalcemia, who was referred for parathyroid scan, in whom the widespread bone marrow techne...
متن کاملThe value of Tc-99m MIBI scintigraphy in active diseases and remission phase of multiple myeloma [Persian]
متن کامل
Effectiveness and complications of 188Re-HEDP in palliative treatment of diffuse skeletal metastases
Introduction: Bone metastases are the most common cause of cancer-related pain in various primary malignant tumors, most often, breast and prostate. 188Re-hydroxyethylidene diphosphonate (188Re-HEDP) is a new and less expensive bone seeking radiopharmaceutical with favorable physical characteristics of the radionuclide such as short half life of 16.9h, maximal β energy of ...
متن کاملNew techniques in nuclear medicine for tumor detection [Persian]
Widespread studies on tumor diagnosis has led to the development of techniques with greater sensitivity and improved specificity for detection of occult and small subclinical tumors. Tumor imaging by radiolabeling of tumor-specific antibodies (Immunoscintigraphy) or tissue specific biochemical agents (Receptor imaging) and especially physiologic imaging with positron emitters (PET), have ...
متن کاملProduction of Holmium-166 DOTMP: A promising agent for bone marrow ablation in hematologic malignancies
Intoduction: Therapeutic radiopharmaceuticals are radiolabeled molecules to deliver sufficient doses of ionizing radiation to specific disease sites such as bone metastases, brain and liver tumors and bone marrows malignancies including multiple myeloma. Among some therapeutic radiopharmaceuticals, 166Ho-1,4,7,10 -tetraazacyclo dodecane-1,4,7,10 tetraethy...
متن کامل